Clinical Trial Update: Sorafenib and Bortezomib Treatment for Relapsed or Refractory Multiple Myeloma Patients [Phase 1, Phase 2]

View source ↗

Summary

This clinical trial update reports results from a Phase 1/2 study evaluating the combination of sorafenib and bortezomib in relapsed or refractory multiple myel…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Bortezomib (bortezomib)
• Sorafenib (Sorafenib)

Snippet

Sponsor: SCRI Development Innovations, LLC | Conditions: Multiple Myeloma | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2013-02-27